Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senaparib and Temozolomide in ARID1A-Mutated Ovarian Cancer
NCT06617923Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of senaparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Objective Response Rate at 3 years. Started Feb 2025; status: active, not recruiting.
02
Drugs
senaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06617923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06617923.